This Medudy course is a video tutorial for physicians on the topic of "Aficamten for obstructive hypertrophic cardiomyopathy". The format used here is a so-called "Journal Club Summary", in which we summarize the latest and most clinically relevant studies for you.
Obstructive hypertrophic cardiomyopathy (HCM) is one of the most common genetic heart diseases and is characterized by a thickened, undilated left ventricle. Aficamten is an oral selective cardiac myosin inhibitor.
This drug reduces the left ventricular outflow tract gradient by attenuating cardiac hypercontractility. Today's study was specifically designed to answer whether aficamten is effective in patients with HCM.
Note: All "speakers" appearing in the Medudy videos are AI-based avatars used to improve the didactics of the videos. The people on whom the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by the Medudy medical team.
At the end of this course you will know
- the clinical background and relevance of the research question under investigation
- the study design and methodology of the publication to answer the research question
- the results and key takeaways of the publication
- the conclusion of the publication and possible limitations
